Titre : Erreurs innées du métabolisme lipidique

Erreurs innées du métabolisme lipidique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Movement Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Erreurs innées du métabolisme lipidique : Questions médicales les plus fréquentes", "headline": "Erreurs innées du métabolisme lipidique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Erreurs innées du métabolisme lipidique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-12", "dateModified": "2025-05-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Erreurs innées du métabolisme lipidique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Erreurs innées du métabolisme", "url": "https://questionsmedicales.fr/mesh/D008661", "about": { "@type": "MedicalCondition", "name": "Erreurs innées du métabolisme", "code": { "@type": "MedicalCode", "code": "D008661", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syndrome de Barth", "alternateName": "Barth Syndrome", "url": "https://questionsmedicales.fr/mesh/D056889", "about": { "@type": "MedicalCondition", "name": "Syndrome de Barth", "code": { "@type": "MedicalCode", "code": "D056889", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.224" } } }, { "@type": "MedicalWebPage", "name": "Hyperlipidémie familiale mixte", "alternateName": "Hyperlipidemia, Familial Combined", "url": "https://questionsmedicales.fr/mesh/D006950", "about": { "@type": "MedicalCondition", "name": "Hyperlipidémie familiale mixte", "code": { "@type": "MedicalCode", "code": "D006950", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.450" } } }, { "@type": "MedicalWebPage", "name": "Hyperlipoprotéinémie de type I", "alternateName": "Hyperlipoproteinemia Type I", "url": "https://questionsmedicales.fr/mesh/D008072", "about": { "@type": "MedicalCondition", "name": "Hyperlipoprotéinémie de type I", "code": { "@type": "MedicalCode", "code": "D008072", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.465" } } }, { "@type": "MedicalWebPage", "name": "Hyperlipoprotéinémie de type II", "alternateName": "Hyperlipoproteinemia Type II", "url": "https://questionsmedicales.fr/mesh/D006938", "about": { "@type": "MedicalCondition", "name": "Hyperlipoprotéinémie de type II", "code": { "@type": "MedicalCode", "code": "D006938", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.481" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hypercholestérolémie familiale homozygote", "alternateName": "Homozygous Familial Hypercholesterolemia", "url": "https://questionsmedicales.fr/mesh/D000090542", "about": { "@type": "MedicalCondition", "name": "Hypercholestérolémie familiale homozygote", "code": { "@type": "MedicalCode", "code": "D000090542", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.481.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Hyperlipoprotéinémie de type III", "alternateName": "Hyperlipoproteinemia Type III", "url": "https://questionsmedicales.fr/mesh/D006952", "about": { "@type": "MedicalCondition", "name": "Hyperlipoprotéinémie de type III", "code": { "@type": "MedicalCode", "code": "D006952", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.483" } } }, { "@type": "MedicalWebPage", "name": "Hyperlipoprotéinémie de type IV", "alternateName": "Hyperlipoproteinemia Type IV", "url": "https://questionsmedicales.fr/mesh/D006953", "about": { "@type": "MedicalCondition", "name": "Hyperlipoprotéinémie de type IV", "code": { "@type": "MedicalCode", "code": "D006953", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.487" } } }, { "@type": "MedicalWebPage", "name": "Hyperlipoprotéinémie de type V", "alternateName": "Hyperlipoproteinemia Type V", "url": "https://questionsmedicales.fr/mesh/D006954", "about": { "@type": "MedicalCondition", "name": "Hyperlipoprotéinémie de type V", "code": { "@type": "MedicalCode", "code": "D006954", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.493" } } }, { "@type": "MedicalWebPage", "name": "Hypolipoprotéinémies", "alternateName": "Hypolipoproteinemias", "url": "https://questionsmedicales.fr/mesh/D007009", "about": { "@type": "MedicalCondition", "name": "Hypolipoprotéinémies", "code": { "@type": "MedicalCode", "code": "D007009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hypoalphalipoprotéinémies", "alternateName": "Hypoalphalipoproteinemias", "url": "https://questionsmedicales.fr/mesh/D052456", "about": { "@type": "MedicalCondition", "name": "Hypoalphalipoprotéinémies", "code": { "@type": "MedicalCode", "code": "D052456", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.330" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Déficit en lécithine-cholestérol-acyl-transférase", "alternateName": "Lecithin Cholesterol Acyltransferase Deficiency", "url": "https://questionsmedicales.fr/mesh/D007863", "about": { "@type": "MedicalCondition", "name": "Déficit en lécithine-cholestérol-acyl-transférase", "code": { "@type": "MedicalCode", "code": "D007863", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.330.500" } } }, { "@type": "MedicalWebPage", "name": "Maladie de Tangier", "alternateName": "Tangier Disease", "url": "https://questionsmedicales.fr/mesh/D013631", "about": { "@type": "MedicalCondition", "name": "Maladie de Tangier", "code": { "@type": "MedicalCode", "code": "D013631", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.330.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Déficit en lécithine-cholestérol-acyl-transférase", "alternateName": "Lecithin Cholesterol Acyltransferase Deficiency", "url": "https://questionsmedicales.fr/mesh/D007863", "about": { "@type": "MedicalCondition", "name": "Déficit en lécithine-cholestérol-acyl-transférase", "code": { "@type": "MedicalCode", "code": "D007863", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.330.500" } } }, { "@type": "MedicalWebPage", "name": "Maladie de Tangier", "alternateName": "Tangier Disease", "url": "https://questionsmedicales.fr/mesh/D013631", "about": { "@type": "MedicalCondition", "name": "Maladie de Tangier", "code": { "@type": "MedicalCode", "code": "D013631", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.330.750" } } }, { "@type": "MedicalWebPage", "name": "Hypobêtalipoprotéinémies", "alternateName": "Hypobetalipoproteinemias", "url": "https://questionsmedicales.fr/mesh/D006995", "about": { "@type": "MedicalCondition", "name": "Hypobêtalipoprotéinémies", "code": { "@type": "MedicalCode", "code": "D006995", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.440" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Abêtalipoprotéinémie", "alternateName": "Abetalipoproteinemia", "url": "https://questionsmedicales.fr/mesh/D000012", "about": { "@type": "MedicalCondition", "name": "Abêtalipoprotéinémie", "code": { "@type": "MedicalCode", "code": "D000012", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.440.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Abêtalipoprotéinémie", "alternateName": "Abetalipoproteinemia", "url": "https://questionsmedicales.fr/mesh/D000012", "about": { "@type": "MedicalCondition", "name": "Abêtalipoprotéinémie", "code": { "@type": "MedicalCode", "code": "D000012", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.500.440.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Lipidoses", "alternateName": "Lipidoses", "url": "https://questionsmedicales.fr/mesh/D008064", "about": { "@type": "MedicalCondition", "name": "Lipidoses", "code": { "@type": "MedicalCode", "code": "D008064", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.641" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Céroïdes-lipofuscinoses neuronales", "alternateName": "Neuronal Ceroid-Lipofuscinoses", "url": "https://questionsmedicales.fr/mesh/D009472", "about": { "@type": "MedicalCondition", "name": "Céroïdes-lipofuscinoses neuronales", "code": { "@type": "MedicalCode", "code": "D009472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.641.509" } } }, { "@type": "MedicalWebPage", "name": "Syndrome de Sjögren-Larsson", "alternateName": "Sjogren-Larsson Syndrome", "url": "https://questionsmedicales.fr/mesh/D016111", "about": { "@type": "MedicalCondition", "name": "Syndrome de Sjögren-Larsson", "code": { "@type": "MedicalCode", "code": "D016111", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.641.723" } } } ] }, { "@type": "MedicalWebPage", "name": "Xanthomatose cérébrotendineuse", "alternateName": "Xanthomatosis, Cerebrotendinous", "url": "https://questionsmedicales.fr/mesh/D019294", "about": { "@type": "MedicalCondition", "name": "Xanthomatose cérébrotendineuse", "code": { "@type": "MedicalCode", "code": "D019294", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.648.398.925" } } } ], "about": { "@type": "MedicalCondition", "name": "Erreurs innées du métabolisme lipidique", "alternateName": "Lipid Metabolism, Inborn Errors", "code": { "@type": "MedicalCode", "code": "D008052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Carlos R Ferreira", "url": "https://questionsmedicales.fr/author/Carlos%20R%20Ferreira", "affiliation": { "@type": "Organization", "name": "Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States; Rare Disease Institute, Children's National Health System, Washington, DC, United States." } }, { "@type": "Person", "name": "Clara D M van Karnebeek", "url": "https://questionsmedicales.fr/author/Clara%20D%20M%20van%20Karnebeek", "affiliation": { "@type": "Organization", "name": "Departments of Pediatrics and Clinical Genetics, Amsterdam University Medical Centers, Amsterdam, The Netherlands; Department of Pediatrics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada. Electronic address: c.d.vankarnebeek@amstedarmumc.nl." } }, { "@type": "Person", "name": "Jerry Vockley", "url": "https://questionsmedicales.fr/author/Jerry%20Vockley", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, University of Pittsburgh School of Medicine, Department of Human Genetics, Graduate School of Public Health, Pittsburgh, Pennsylvania, USA." } }, { "@type": "Person", "name": "Andrea L Gropman", "url": "https://questionsmedicales.fr/author/Andrea%20L%20Gropman", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Children's National, Washington, DC 20010, USA." } }, { "@type": "Person", "name": "Sumreena Mansoor", "url": "https://questionsmedicales.fr/author/Sumreena%20Mansoor", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, Shifa College of Medicine, Shifa Tameer-e-millat university, H-8/4, Islamabad, Pakistan. dr.sumreena@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Movement disorders in valine métabolism diseases caused by HIBCH and ECHS1 deficiencies.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/36200804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ene.15515" } }, { "@type": "ScholarlyArticle", "name": "Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders.", "datePublished": "2024-06-09", "url": "https://questionsmedicales.fr/article/38929575", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/medicina60060958" } }, { "@type": "ScholarlyArticle", "name": "COVID19-associated new-onset movement disorders: a follow-up study.", "datePublished": "2023-03-21", "url": "https://questionsmedicales.fr/article/36943516", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00415-023-11661-x" } }, { "@type": "ScholarlyArticle", "name": "Prevalence and Treatments of Movement Disorders in Prion Diseases: A Longitudinal Cohort Study.", "datePublished": "2022-07-16", "url": "https://questionsmedicales.fr/article/35841311", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mds.29152" } }, { "@type": "ScholarlyArticle", "name": "Clinical Spectrum, Radiological Correlation and Outcome of Movement Disorders in Wilson's Disease.", "datePublished": "2023-10-09", "url": "https://questionsmedicales.fr/article/37840995", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5334/tohm.794" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies métaboliques et nutritionnelles", "item": "https://questionsmedicales.fr/mesh/D009750" }, { "@type": "ListItem", "position": 3, "name": "Maladies métaboliques", "item": "https://questionsmedicales.fr/mesh/D008659" }, { "@type": "ListItem", "position": 4, "name": "Erreurs innées du métabolisme", "item": "https://questionsmedicales.fr/mesh/D008661" }, { "@type": "ListItem", "position": 5, "name": "Erreurs innées du métabolisme lipidique", "item": "https://questionsmedicales.fr/mesh/D008052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Erreurs innées du métabolisme lipidique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Erreurs innées du métabolisme lipidique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Erreurs innées du métabolisme lipidique", "description": "Comment diagnostique-t-on une erreur métabolique lipidique ?\nQuels tests sont utilisés pour le diagnostic ?\nLes symptômes aident-ils au diagnostic ?\nQuelle est l'importance de l'histoire familiale ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Erreurs innées du métabolisme lipidique", "description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils selon le type d'erreur ?\nY a-t-il des signes cutanés associés ?\nLes symptômes apparaissent-ils à la naissance ?\nLes troubles mentaux sont-ils possibles ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Erreurs innées du métabolisme lipidique", "description": "Peut-on prévenir ces erreurs ?\nLe conseil génétique est-il utile ?\nLes vaccinations sont-elles importantes ?\nLes tests prénataux sont-ils recommandés ?\nL'éducation des parents est-elle cruciale ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Erreurs innées du métabolisme lipidique", "description": "Quels traitements sont disponibles ?\nLa diététique joue-t-elle un rôle ?\nDes médicaments sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes greffes d'organes sont-elles nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Erreurs innées du métabolisme lipidique", "description": "Quelles complications peuvent survenir ?\nLes erreurs lipidique peuvent-elles être mortelles ?\nY a-t-il des risques de cancer ?\nLes troubles psychologiques sont-ils fréquents ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Erreurs innées du métabolisme lipidique", "description": "Quels sont les facteurs de risque génétiques ?\nL'origine ethnique influence-t-elle le risque ?\nL'alimentation joue-t-elle un rôle ?\nLes infections peuvent-elles aggraver la condition ?\nLe sexe influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D008052?mesh_terms=Movement+Disorders&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on une erreur métabolique lipidique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins, des analyses génétiques et des biopsies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage néonatal, des dosages enzymatiques et des analyses d'urine sont courants." } }, { "@type": "Question", "name": "Les symptômes aident-ils au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes cliniques orientent le diagnostic et peuvent indiquer le type d'erreur." } }, { "@type": "Question", "name": "Quelle est l'importance de l'histoire familiale ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'histoire familiale aide à identifier les risques génétiques et à orienter les tests." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les organes affectés, mais n'est pas spécifique." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleurs abdominales, troubles neurologiques et retard de croissance." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type d'erreur ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type d'erreur lipidique présente des symptômes spécifiques et variés." } }, { "@type": "Question", "name": "Y a-t-il des signes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines erreurs peuvent provoquer des dépôts lipidiques visibles sur la peau." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils à la naissance ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent apparaître dès la naissance, d'autres se développent plus tard." } }, { "@type": "Question", "name": "Les troubles mentaux sont-ils possibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles cognitifs et comportementaux peuvent survenir dans certaines erreurs." } }, { "@type": "Question", "name": "Peut-on prévenir ces erreurs ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est limitée, mais le dépistage néonatal peut aider à identifier les cas précoces." } }, { "@type": "Question", "name": "Le conseil génétique est-il utile ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le conseil génétique aide les familles à comprendre les risques et les options de dépistage." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne préviennent pas les erreurs métaboliques, mais protègent contre d'autres maladies." } }, { "@type": "Question", "name": "Les tests prénataux sont-ils recommandés ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des tests prénataux peuvent être proposés pour détecter certaines erreurs génétiques." } }, { "@type": "Question", "name": "L'éducation des parents est-elle cruciale ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les parents sur les signes et symptômes peut aider à une détection précoce." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des régimes alimentaires spécifiques, des suppléments et des médicaments." } }, { "@type": "Question", "name": "La diététique joue-t-elle un rôle ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un régime adapté est crucial pour gérer les niveaux de lipides et prévenir les complications." } }, { "@type": "Question", "name": "Des médicaments sont-ils utilisés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments peuvent être prescrits pour réduire les niveaux de lipides ou traiter les symptômes." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche pour certaines erreurs, mais n'est pas encore courante." } }, { "@type": "Question", "name": "Les greffes d'organes sont-elles nécessaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas graves, des greffes peuvent être envisagées pour traiter des dommages organiques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies hépatiques, des troubles neurologiques et des problèmes cardiaques." } }, { "@type": "Question", "name": "Les erreurs lipidique peuvent-elles être mortelles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines erreurs peuvent entraîner des complications graves pouvant être fatales sans traitement." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines erreurs peuvent augmenter le risque de développer certains types de cancer." } }, { "@type": "Question", "name": "Les troubles psychologiques sont-ils fréquents ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles psychologiques peuvent survenir en raison de l'impact des symptômes." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes sans traitement." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque génétiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux d'erreurs métaboliques augmentent le risque de transmission." } }, { "@type": "Question", "name": "L'origine ethnique influence-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines erreurs sont plus fréquentes dans des populations spécifiques en raison de la génétique." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les individus prédisposés." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver la condition ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent déclencher ou aggraver les symptômes des erreurs métaboliques." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines erreurs métaboliques peuvent avoir une prévalence différente selon le sexe." } } ] } ] }

Sous-catégories

18 au total
└─

Syndrome de Barth

Barth Syndrome D056889 - C18.452.648.398.224
└─

Hyperlipidémie familiale mixte

Hyperlipidemia, Familial Combined D006950 - C18.452.648.398.450
└─

Hyperlipoprotéinémie de type I

Hyperlipoproteinemia Type I D008072 - C18.452.648.398.465
└─

Hyperlipoprotéinémie de type II

Hyperlipoproteinemia Type II D006938 - C18.452.648.398.481
└─

Hyperlipoprotéinémie de type III

Hyperlipoproteinemia Type III D006952 - C18.452.648.398.483
└─

Hyperlipoprotéinémie de type IV

Hyperlipoproteinemia Type IV D006953 - C18.452.648.398.487
└─

Hyperlipoprotéinémie de type V

Hyperlipoproteinemia Type V D006954 - C18.452.648.398.493
└─

Hypolipoprotéinémies

Hypolipoproteinemias D007009 - C18.452.648.398.500
└─

Lipidoses

Lipidoses D008064 - C18.452.648.398.641
└─

Xanthomatose cérébrotendineuse

Xanthomatosis, Cerebrotendinous D019294 - C18.452.648.398.925
└─└─

Hypercholestérolémie familiale homozygote

Homozygous Familial Hypercholesterolemia D000090542 - C18.452.648.398.481.500
└─└─

Hypoalphalipoprotéinémies

Hypoalphalipoproteinemias D052456 - C18.452.648.398.500.330
└─└─

Hypobêtalipoprotéinémies

Hypobetalipoproteinemias D006995 - C18.452.648.398.500.440
└─└─

Céroïdes-lipofuscinoses neuronales

Neuronal Ceroid-Lipofuscinoses D009472 - C18.452.648.398.641.509
└─└─

Syndrome de Sjögren-Larsson

Sjogren-Larsson Syndrome D016111 - C18.452.648.398.641.723
└─└─└─

Déficit en lécithine-cholestérol-acyl-transférase

Lecithin Cholesterol Acyltransferase Deficiency D007863 - C18.452.648.398.500.330.500
└─└─└─

Maladie de Tangier

Tangier Disease D013631 - C18.452.648.398.500.330.750
└─└─└─

Abêtalipoprotéinémie

Abetalipoproteinemia D000012 - C18.452.648.398.500.440.500

Sources (10000 au total)

Movement disorders in valine métabolism diseases caused by HIBCH and ECHS1 deficiencies.

HIBCH and ECHS1 genes encode two enzymes implicated in the critical steps of valine catabolism, 3-hydroxyisobutyryl-coenzyme A (CoA) hydrolase (HIBCH) and short-chainenoyl-CoA hydratase (ECHS1), respe... We reviewed a series of 18 patients (HIBCHD: 5; ECHS1D: 13) as well as 105 patients from the literature. We analysed the detailed phenotype of HIBCHD (38 patients) and ECHS1D (85 patients), focusing o... The two diseases have a very similar neurological phenotype, with an early onset before 10 years of age for three clinical presentations: neonatal onset, Leigh-like syndrome (progressive onset or acut... Movement disorders, including abnormal ocular movements, are a hallmark of HIBCHD and ECHS1D. MDs are not uniform; dystonia is the most frequent, and various types of MD are combined in single patient...

COVID19-associated new-onset movement disorders: a follow-up study.

Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited.... Cases with new-onset COVID-19-associated movement disorders were identified by searching the literature. Authors were contacted for outcome data which were reviewed and analyzed.... Movement disorders began 12.6 days on average after the initial onset of COVID-19. 92% of patients required hospital admission (mean duration 23 days). In a fraction of patients (6 of 27; 22%; 4 males... The prognosis of new-onset COVID-19-associated movement disorder appears to be generally good. The majority recovered without residual symptoms within several weeks or months. Permanent cases may be d...

Prevalence and Treatments of Movement Disorders in Prion Diseases: A Longitudinal Cohort Study.

Prion diseases cause a range of movement disorders involving the cortical, extrapyramidal, and cerebellar systems, and yet there are no large systematic studies of their prevalence, features, associat... We sought to describe the natural history and pharmacological management of movement disorders in prion diseases.... We studied the serial examination findings, investigation results, and symptomatic treatment recorded for 700 patients with prion diseases and 51 mimics who had been enrolled onto the prospective long... Gait disturbances, myoclonus, and increased tone are the most frequently observed movement disorders in patients with prion diseases. The typical pattern of early motor dysfunction involves gait distu... We describe the prevalence, severity, evolution, treatment, and associated features of movement disorders in prion diseases based on a prospective cohort study. © 2022 The Authors. Movement Disorders ...

Clinical Spectrum, Radiological Correlation and Outcome of Movement Disorders in Wilson's Disease.

Movement disorders are the commonest clinical presentation in patients with neurological Wilson's disease (NWD). There are very few studies evaluating the spectrum, severity and their correlation with... To study the spectrum, topographic distribution, radiological correlate, temporal course and outcome in our cohort of NWD patients.... Retrospective chart review of the NWD patients having movement disorders was performed and analyzed.... Sixty-nine patients (males- 47) with NWD were analysed and the mean age at the onset of neurological symptoms was 13.6 ± 6.6 years (median 13 years; range 7-37 years). The first neurological symptom w... Dystonia is the most common movement disorder in NWD in isolation or in combination with parkinsonism and tremors. Putamen is the most common radiological site of lesions and more frequently affected ...

Movement Disorders in Brain Sagging Syndrome Due To Spontaneous Intracranial Hypotension: A Review.

Spontaneous intracranial hypotension (SIH), a treatable condition that stems from spinal leakage of cerebrospinal fluid, usually presents with orthostatic headache, nausea, vomiting, dizziness, and ti... The authors performed a literature search in PubMed in July 2024 using the Boolean phrase-... We tabulated 21 case reports/series that highlighted the presence of movement disorders. The most reported phenomenology is gait unsteadiness. While it usually emerges in the background of the classic... Brain sagging syndrome due to SIH may present with a wide range of movement disorders. Mechanical distortion of the posterior fossa and subcortical structures result in the emergence of such movement ...

Individualized Physiotherapy of Upper Body Functional Movement Disorder - Two Illustrative Cases.

Information on specialist physiotherapeutic treatment for functional movement disorders is scarce. Previous studies focussed on functional gait disorders and availability of descriptions of the practi... We present two illustrative cases, demonstrating the key elements of physiotherapy for the treatment of functional movement disorders beyond gait difficulties. The individual applicability of the spec... Thus, our case series are intended to guide clinicians and therapists alike, to promote disease-specific physiotherapy for this common and treatable neuropsychiatric disorder....

Forearm bisection task suggests an alteration in body schema in patients with functional movement disorders (motor conversion disorders).

To explore potential alterations of the Body Schema, the implicit sensorimotor representation of one's own body, in patients with Functional Movement Disorders (FMD, Motor Conversion Disorders), chara... 10 FMD patients and 11 healthy controls (HC) underwent the Forearm Bisection Task, aimed at assessing perceived body metrics, which consists in asking the subject, blindfolded, to repeatedly point at ... FMD patients bisected their forearm more proximally (with an increased shift towards their elbow equal to 7.5%) with respect to HC; average bisection point was positively associated with anxiety level... FMD patients perceive their forearm as shorter than HC, suggesting an alteration of their Body Schema. The Body Schema can go through short- and long-term updates in the life course, mainly related to...

Movement disorders associated with substance use in adults living in precarious housing or homelessness.

Many individuals living in precarious housing or homelessness have multimorbid illnesses, including substance use, psychiatric, and neurological disorders. Movement disorders (MDs) associated substanc... Participants were recruited from an impoverished urban neighborhood and were assessed for substance dependence and self-reported substance use (alcohol, cannabis, cocaine, methamphetamine, nicotine, a... The proportion of the sample with clinically relevant signs of MDs in any of the four categories was 18.6% (n = 401), and these participants demonstrated lower levels of functioning than those without... Our study found a high proportion of MDs in a relatively young sample, and their severity was consistently associated with methamphetamine use, moderated by participant demographics and antipsychotic ...

GNAO1-related movement disorder: An update on phenomenology, clinical course, and response to treatments.

To evaluate clinical phenotype and molecular findings of 157 cases with GNAO1 pathogenic or likely pathogenic variants delineating the clinical spectrum, course, and response to treatments.... Clinical phenotype, genetic data, and pharmacological and surgical treatment history of 11 novel cases and 146 previously published patients were analyzed.... Complex hyperkinetic movement disorder (MD) characterizes 88% of GNAO1 patients. Severe hypotonia and prominent disturbance of postural control seem to be hallmarks in the early stages preceding the h... Infantile or childhood-onset complex hyperkinetic MD (chorea and/or dystonia) with or without paroxysmal exacerbations, associated hypotonia, and developmental disorders should prompt research for GNA...